If you have a Roundup-related cancer claim, a critical decision point is approaching. Bayer has secured preliminary court approval for its proposed Roundup class action settlement—but on April 27, 2026, the US Supreme Court will hear oral arguments on whether federal law preempts (bars) some of your strongest claims. This 30-day gap between now and the SCOTUS hearing is the window where you need to decide: accept Bayer's settlement offer now, or wait to see if the Supreme Court backs your claims.
The federal judge presiding over the Roundup multidistrict litigation (MDL) has given the green light to let Bayer's settlement proposal move forward to a fairness hearing and final approval vote. This is a major procedural win for Bayer—it means the court found the settlement terms reasonable and that the settlement class (all eligible Roundup claimants) was properly defined.
But "preliminary" is the operative word. The settlement is not yet binding. Claimants still have the right to opt out, object, or ask the court to reject the entire deal. And the Supreme Court's preemption ruling could fundamentally alter the settlement's value.
Under the proposed terms, Bayer is offering compensation for qualifying Roundup claimants. The exact payout structure depends on cancer type and medical evidence. Bayer has already spent $11 billion on Roundup settlements, verdicts, and legal fees since 2018—a number that signals both the scale of claims and Bayer's appetite to end litigation.
Bayer's core argument: federal herbicide regulations—specifically EPA approval of glyphosate (the active ingredient in Roundup)—preempt state-law cancer claims. In other words, because the EPA has already deemed glyphosate safe, you shouldn't be able to sue Bayer in state court for failing to warn about cancer risks.
This is not a new argument. Bayer has been making it for years. But the Supreme Court has never definitively ruled on whether herbicide preemption applies to Roundup. The April 27 oral arguments will focus on two core questions:
If SCOTUS sides with Bayer, preemption wins, and many state-law claims vanish. Your leverage as a claimant drops. If SCOTUS sides with claimants' lawyers, your claims survive and remain valuable—possibly more valuable than Bayer's current settlement offer.
Bayer has made clear: if Roundup litigation continues unchecked, it will consider pushing Monsanto (the Roundup subsidiary) into bankruptcy. This is a pressure tactic, but it's also a credible one. Bankruptcy would trigger an automatic stay on litigation, force all claims into a single channel, and likely reduce payout amounts across the board.
From Bayer's perspective, bankruptcy is the "scorched earth" option—and they're letting claimants know it's on the table. From your perspective, it's a reason to think carefully about settlement timing. If SCOTUS rules against preemption on April 27, claimants' leverage spikes, and a Monsanto bankruptcy becomes less likely. Bayer would probably negotiate higher settlement values. Conversely, if SCOTUS rules for preemption, claims weaken, Bayer's position strengthens, and bankruptcy threats become more credible.
Here's the dilemma: Bayer's preliminary settlement offer is on the table right now. But the Supreme Court won't rule until weeks or months after April 27. Waiting for that ruling could expose you to risk—Bayer could walk away from the settlement if SCOTUS rules in their favor, or they could lower their offer if preemption wins.
Conversely, settling now locks in certain money, but you forfeit the upside if SCOTUS backs claimants. If you believe the Court will rule against preemption, waiting could be worth it. If you're uncertain, settling is the safe play.
Factors to weigh:
Since acquiring Monsanto in 2018, Bayer has paid out over $11 billion in Roundup settlements, jury verdicts, and legal costs. That number includes:
This spending shows Bayer's willingness to pay, but it also shows they're motivated to end the litigation. The April 27 SCOTUS ruling is the last major legal unknown. If it goes Bayer's way, they've bought themselves a massive discount on remaining claims. If it goes claimants' way, Bayer's appetite to settle will remain strong.
Even after SCOTUS rules, the Roundup settlement process will take months. Here's the probable timeline:
Claimants who settle now will start receiving payments sooner. Claimants who wait could see higher payouts if SCOTUS rules in their favor—or lower payouts if Bayer adjusts its offer after a preemption win.
You're in a rare position: a preliminary settlement that's subject to a major Supreme Court ruling. This is not a typical "take it or leave it" scenario. Your decision should hinge on your medical evidence, financial need, and tolerance for uncertainty. If your case is strong, you can afford to wait, and you believe SCOTUS will reject preemption, holding out could pay off. If you need money soon or your evidence is borderline, Bayer's offer may be the smarter play.
The April 27 SCOTUS hearing is a turning point. But it's not the only decision point—your decision to settle or wait is just as critical.